Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.

British journal of clinical pharmacology - 1 Jan 2016

Hopkins Ashley M, Wiese Michael D, Proudman Susanna M, O'Doherty Catherine E, Upton Richard N, Foster David J R

Abstract excerpt

AIM: Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity. The aim was to develop a time-to-event model describing leflunomide cessation due to toxicity within a clinical cohort and to investigate potential predictors of cessation such as total and free teriflunomide exposure and pharmacogenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Cytochrome P-450 CYP1A2

Share to Hydroxybutyrates

Share to Isoxazoles

Share to Nitriles

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 26331989
DOI: 10.1111/bcp.12760
PMCID: PMC4693574

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.PMID 26331989Read ↗

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Semantic proximity Read ↗

Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.Semantic proximity Read ↗

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.Semantic proximity Read ↗

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.Semantic proximity Read ↗

An international study to investigate and optimise the safety of discontinuing valproate in young men and women with epilepsy: protocolSemantic proximity Read ↗

Colchicine discontinuation in familial Mediterranean fever: short-term outcomes by pre-discontinuation attack frequency.Semantic proximity Read ↗

Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss Clinical Quality Management cohortSemantic proximity Read ↗

Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.Semantic proximity Read ↗

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.Semantic proximity Read ↗

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read ↗

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.Semantic proximity Read ↗

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target In Patients With Rheumatoid Arthritis: A Nationwide Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.